These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33867440)

  • 1. Is serum endocan a sensitive biomarker for early recurrence of hepatocellular carcinoma after radiofrequency ablation?
    Omar SA; Attia NM; Sheir MI; Amer AS; El Shabrawy MM; Hasan BB
    Eur J Gastroenterol Hepatol; 2021 Jul; 33(7):1015-1022. PubMed ID: 33867440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.
    Ziol M; Sutton A; Calderaro J; Barget N; Aout M; Leroy V; Blanc JF; Sturm N; Bioulac-Sage P; Nahon P; Nault JC; Charnaux N; N'kontchou G; Trinchet JC; Delehedde M; Seror O; Beaugrand M; Vicaut E; Ganne-Carrié N
    J Hepatol; 2013 Dec; 59(6):1264-70. PubMed ID: 23928407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation.
    Siripongsakun S; Wei SH; Lin S; Chen J; Raman SS; Sayre J; Tong MJ; Lu DS
    J Gastroenterol Hepatol; 2014 Jan; 29(1):157-64. PubMed ID: 24354994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence.
    Yang W; Chen MH; Yin SS; Yan K; Gao W; Wang YB; Huo L; Zhang XP; Xing BC
    AJR Am J Roentgenol; 2006 May; 186(5 Suppl):S275-83. PubMed ID: 16632688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.
    Gao Y; Zheng DY; Cui Z; Ma Y; Liu YZ; Zhang W
    World J Gastroenterol; 2015 Sep; 21(36):10418-26. PubMed ID: 26420968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy].
    Yang W; Chen MH; Yan K; Gao W; Yin SS; Wang YB; Zhang XP; Xing BC; Huang XF
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):980-4. PubMed ID: 16194353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
    Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y
    Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma.
    Yoon JH; Goo YJ; Lim CJ; Choi SK; Cho SB; Shin SS; Jun CH
    World J Gastroenterol; 2020 Aug; 26(32):4833-4845. PubMed ID: 32921960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for hepatocellular carcinoma.
    Jeon HJ; Eun HS; Kwon IS; Lee BS; Lee ES; Rou WS; Sung JK; Moon HS; Kang SH; Lee HS; Kim SH; Chun K; Kim SH
    Surg Endosc; 2023 Jul; 37(7):5176-5189. PubMed ID: 36947227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of ultrasound-guided radiofrequency ablation for primary hepatocellular carcinoma near the liver surface].
    Wu J; Lin S; Wu W; Yan K; Dai Q; Chen M
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):933-7. PubMed ID: 26887624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the risk factors for recurrence of early and late stage hepatocellular carcinoma after hepatic artery embolization combined with radiofrequency ablation therapy].
    Sun Y; Zhang HH; Zheng JS; Zhang YH
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):1001-1005. PubMed ID: 34814396
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    Nault JC; Guyot E; Laguillier C; Chevret S; Ganne-Carrie N; N'Kontchou G; Beaugrand M; Seror O; Trinchet JC; Coelho J; Lasalle P; Charnaux N; Delehedde M; Sutton A; Nahon P
    Cancer Epidemiol Biomarkers Prev; 2013 Aug; 22(8):1343-52. PubMed ID: 23780836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival.
    Yang Y; Chen Y; Ye F; Cao X; Xin Y; Wang Y; Lei Y; Li X; Feng D; Zhou X; Fan Q
    Eur Radiol; 2021 May; 31(5):3053-3064. PubMed ID: 33175203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma invading portal venous system in cirrhosis: long-term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study.
    Giorgio A; Calisti G; Montesarchio L; Scognamiglio U; Matteucci P; Coppola C; Scarano F; Amendola F; Giorgio V
    Anticancer Res; 2014 Nov; 34(11):6785-90. PubMed ID: 25368292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma.
    Yoo J; Lee MW; Lee DH; Lee JH; Han JK
    Liver Int; 2020 May; 40(5):1189-1200. PubMed ID: 32056353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.
    Tan Y; Wang X; Ma K; Zhang L; Li J; Chen P; Zhang B
    Int J Hyperthermia; 2022; 39(1):190-199. PubMed ID: 35042449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.
    Teng W; Jeng WJ; Chen WT; Lin CC; Lin CY; Lin SM; Sheen IS
    Cancer Med; 2022 Oct; 11(20):3786-3795. PubMed ID: 35435327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation.
    Ho PH; Teng W; Lin CC; Jeng WJ; Chen WT; Lin CY; Lin SM; Sheen IS
    Int J Hyperthermia; 2020; 37(1):1008-1015. PubMed ID: 32814458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
    J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.